Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Vaccines

Free Subscription 16.02.2026 1 Arch Pediatr 1 BMJ 1 Indian Pediatr 3 J Infect Dis 1 J Pediatr 1 J Virol 1 JAMA 1 N Engl J Med 2 Pediatr Infect Dis J 2 PLoS Med 7 PLoS One 1 Science 24 Vaccine 3 Virology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Arch Pediatr

1. DAUNGSUPAWONG H, Wiwanitkit V
   Re: Vaccinating children against SARS-CoV-2 - parents' attitude.
   Arch Pediatr. 2026 Feb 9:105478. doi: 10.1016/j.arcped.2026.105478.
   PubMed        
   
   

   
   BMJ

2. BARANIUK C
   US and Moderna: FDA refuses approval process for new mRNA flu vaccine.
   BMJ. 2026;392:s287.
   PubMed        
   
   

   
   Indian Pediatr

3. MEHNDIRATTA S
   Enhancing Influenza Vaccination Strategies for Immunocompromised Children in India.
   Indian Pediatr. 2026 Feb 11. doi: 10.1007/s13312-026-00288.
   PubMed        
   
   

   
   J Infect Dis

4. NAIR N, Friese J, Schreur PJW, Osterhaus ADME, et al
   Efficient sensing of a four-segmented Rift Valley fever virus vaccine candidate by human monocytes.
   J Infect Dis. 2026 Feb 13:jiag085. doi: 10.1093.
   PubMed         Abstract available
   
   
5. COULTER FJ, Micheletti CA, Estrada AE, Luo S, et al
   New insights into an old vaccine: potency and breadth of neutralizing antibodies elicited by the yellow fever vaccine 17D are boosted by heterologous Orthoflavivirus infection.
   J Infect Dis. 2026 Feb 11:jiag077. doi: 10.1093.
   PubMed         Abstract available
   
   
6. SAUER KM, Fumero EF, Cornely OA, Nordlander A, et al
   Beyond Antibodies: Influenza vaccine induced T-Cell-Response in Hematological Malignancy.
   J Infect Dis. 2026 Feb 10:jiag079. doi: 10.1093.
   PubMed        
   
   

   
   J Pediatr

7. SMITH MJ, Harrington TA, Chung RJ, Rountree W, et al
   Preventing Post-Vaccination Presyncope and Syncope in Adolescents: A Randomized Controlled Trial of a Clinic-Based Intervention.
   J Pediatr. 2026 Feb 13:115035. doi: 10.1016/j.jpeds.2026.115035.
   PubMed         Abstract available
   
   

   
   J Virol

8. PATEL J, Yang Z, Ping S, Ahmed A, et al
   The magnitude and durability of neutralizing antibody responses to human papillomavirus vaccine do not depend on DNA sensing pathways.
   J Virol. 2026 Feb 10:e0215025. doi: 10.1128/jvi.02150.
   PubMed         Abstract available
   
   

   
   JAMA

9. MOSER CA, Offit PA
   Aluminum Exposure From Vaccines and Diet.
   JAMA. 2026 Feb 9. doi: 10.1001/jama.2026.0056.
   PubMed        
   
   

   
   N Engl J Med

10. WANG JJ, Schonborn L, Warkentin TE, Muller L, et al
    Adenoviral Inciting Antigen and Somatic Hypermutation in VITT.
    N Engl J Med. 2026;394:669-683.
    PubMed         Abstract available
    
    

    
    Pediatr Infect Dis J

11. AGARWAL A, Rana S, Mathur SB, Manchanda V, et al
    Immunogenicity of Three-session Intradermal Rabies Post-exposure Prophylaxis in Indian Children and Adolescents.
    Pediatr Infect Dis J. 2025 Sep 17. doi: 10.1097/INF.0000000000005004.
    PubMed         Abstract available
    
    
12. PLOTKIN SA
    Evidence for the Effectiveness of COVID-19 Vaccine in Children.
    Pediatr Infect Dis J. 2026 Feb 11. doi: 10.1097/INF.0000000000005157.
    PubMed        
    
    

    
    PLoS Med

13. CARVALHO N, Watts E, Oliver VL, Clark A, et al
    Evaluation of rotavirus, pneumococcal conjugate and human papillomavirus vaccination in four Pacific island countries: A cost-effectiveness modelling study.
    PLoS Med. 2026;23:e1004604.
    PubMed         Abstract available
    
    
14. TANVIR H, Clark RA, Sumner T, Horton KC, et al
    Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling study.
    PLoS Med. 2026;23:e1004595.
    PubMed         Abstract available
    
    

    
    PLoS One

15. CHEN F, Nakanishi H, Sekizawa Y, Ochi S, et al
    Correction: Investigating the causal effects of COVID-19 vaccination on the adoption of protective behaviors in Japan: Insights from a fuzzy regression discontinuity design.
    PLoS One. 2026;21:e0342590.
    PubMed         Abstract available
    
    
16. KO Y, Seo Y, Park JJ, Kim EJ, et al
    Smallpox outbreak scenarios and reactive intervention protocols: A mathematical model-based analysis applied to the Republic of Korea.
    PLoS One. 2026;21:e0315072.
    PubMed         Abstract available
    
    
17. HASMUKHARAY K, Verma AK, Aravindhan K, Alagappan PRS, et al
    Prospective Evaluation of Antibody Response post COVID-19 vaccination in older persons >== 60 years old (PEARL 60): A longitudinal 15-months study in a tertiary centre in Malaysia.
    PLoS One. 2026;21:e0340891.
    PubMed         Abstract available
    
    
18. VOLKMAN HR, de Munter L, Nguyen JL, Tran TMP, et al
    Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform.
    PLoS One. 2026;21:e0342382.
    PubMed         Abstract available
    
    
19. SANJO-ODUTAYO A, Oyibo P, Eyawo O
    Parental perspectives on human papillomavirus (HPV) vaccination of school-aged girls in Ilishan, Nigeria: A qualitative study protocol.
    PLoS One. 2026;21:e0341563.
    PubMed         Abstract available
    
    
20. HAILE AW, Kebede EB, Bagilkar V, Mamo TW, et al
    Uptake of measles second dose vaccine among children aged 15-35 months at Mettu Woreda, Illu Aba Bor Zone, Ethiopia: A community-based cross-sectional study.
    PLoS One. 2026;21:e0342931.
    PubMed         Abstract available
    
    
21. AHMAD S, Aslam S, Khalid A
    Multi-epitope vaccine design against Monkeypox virus: An immunoinformatics approach.
    PLoS One. 2026;21:e0342087.
    PubMed         Abstract available
    
    

    
    Science

22. VOGEL G, Kupferschmidt K
    Rare, dangerous side effects from COVID-19 vaccines explained.
    Science. 2026;391:647-648.
    PubMed         Abstract available
    
    

    
    Vaccine

23. HELBLE M, Nannei C, Friede M, Nicholson MW, et al
    Pathways to economically viable and sustainable vaccine manufacturing in LMICs.
    Vaccine. 2026 Feb 14:128273. doi: 10.1016/j.vaccine.2026.128273.
    PubMed         Abstract available
    
    
24. ABBAD A, Lerman B, Ehrenhaus J, Ojeda DS, et al
    Corrigendum to "Sustained superior humoral immune responses of mRNA vaccines compared to Sputnik V viral vector COVID-19 vaccines in naive and convalescent populations" [Vaccine 70 (2026) 128018].
    Vaccine. 2026;77:128333.
    PubMed        
    
    
25. IMANISHI Y, Iorini M, Wada I, Jwa S, et al
    Child sexual abuse and adult vaccination: Opposing patterns between routine and pandemic vaccines in a Nationwide survey.
    Vaccine. 2026;76:128299.
    PubMed         Abstract available
    
    
26. MAKI W, Ishitsuka K, Morisaki N, Machida M, et al
    Association of parental vaccination readiness and descriptive norms with childhood vaccination status.
    Vaccine. 2026;76:128337.
    PubMed         Abstract available
    
    
27. BROGAN D, Prabhu PS, Deng L, Sharma K, et al
    Vaccination under sedation in children with needle phobia or behavioural difficulties: A retrospective study.
    Vaccine. 2026;76:128352.
    PubMed         Abstract available
    
    
28. RADIA K, Sapuan S, Grassly N, Andrews N, et al
    An observational, cohort, multi-centre, open label phase IV extension study comparing IPV immune responses to preschool dTaP-IPV booster vaccines in children whose mothers received or did not receive an IPV-containing pertussis vaccine during pregnanc
    Vaccine. 2026;76:128306.
    PubMed         Abstract available
    
    
29. STICCHI L, Di Biagio A, Domnich A, Inglese M, et al
    Immunogenicity and safety of two doses of the four-component recombinant meningococcal B (4CMenB) vaccine in adults with immunodeficiency.
    Vaccine. 2026;76:128295.
    PubMed         Abstract available
    
    
30. OGAWA T, Sunyi J, Kawachi K, Murakami J, et al
    Regulatory approaches for platform-based vaccine development in Japan: Insights from PMDA's experience with COVID-19 and RSV vaccines.
    Vaccine. 2026;76:128315.
    PubMed         Abstract available
    
    
31. YAN X, Hu X, Xu Y, Zhang X, et al
    Herpes zoster vaccination coverage and associated factors among individuals aged >/=50 years in Zhejiang, China: A population-based cross-sectional study.
    Vaccine. 2026;76:128301.
    PubMed         Abstract available
    
    
32. STEFFENS M, Bolsewicz K, Prokopovich K, Beard F, et al
    Immunisation program managers' experiences of implementing the change from a two dose to a single dose course of HPV vaccination in Australia's school-based program.
    Vaccine. 2026;76:128300.
    PubMed         Abstract available
    
    
33. KRISTOFFERSEN AB, Boas H, Meijerink H, LeBlanc M, et al
    Increasing incidence of pertussis before scheduled primary school booster vaccinations in Norway, 1998-2019.
    Vaccine. 2026;76:128309.
    PubMed         Abstract available
    
    
34. OYEDELE T, Park R, Morales K, Jain M, et al
    A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial.
    Vaccine. 2026;76:128304.
    PubMed         Abstract available
    
    
35. GREWAL R, Alessandrini J, Wilson SE, Hernandez A, et al
    Human papillomavirus (HPV) vaccine coverage and associated sociodemographic factors among individuals eligible for publicly funded vaccine in Ontario, Canada from 2007 to 2023: A Canadian immunization research network study.
    Vaccine. 2026;76:128303.
    PubMed         Abstract available
    
    
36. CAO Q, Du S, Yang K, Liu M, et al
    Assessing the impact of SARS-CoV-2 infection and vaccination on fertility and assisted reproductive techniques outcomes: an umbrella review.
    Vaccine. 2026;76:128293.
    PubMed         Abstract available
    
    
37. URIU K, Kaku Y, Kosugi Y, Chen L, et al
    Humoral immunity induced by XEC monovalent vaccines against SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2.
    Vaccine. 2026;76:128311.
    PubMed         Abstract available
    
    
38. LU Y, Tang C, Xu S, Hussain I, et al
    Understanding parental HPV vaccination decision in China through the lens of vaccine hesitancy and preference heterogeneity: a discrete choice experiment.
    Vaccine. 2026;76:128307.
    PubMed         Abstract available
    
    
39. SIDEBOTHAM E, Caldwell DM, Davies SR, Thornton ZA, et al
    Interventions to increase vaccine uptake among socially excluded groups: A systematic review.
    Vaccine. 2026;76:128314.
    PubMed         Abstract available
    
    
40. SEMPRINI J, Brandt H
    Exploring rural-urban disparities in HPV vaccine initiation: new insights from the 2022 national health interview survey.
    Vaccine. 2026;76:128334.
    PubMed         Abstract available
    
    
41. TIWANA MH, Smith J
    Structural determinants of vaccine access: an integrated review of the Canadian literature.
    Vaccine. 2026;76:128324.
    PubMed         Abstract available
    
    
42. THUMAR R, Shekh SL, Chauhan A, Kapoor K, et al
    Immunoinformatics design and in vivo evaluation of a multiepitope vaccine targeting OMPL1, Lipl32, Lipl41, and Lipl46 for leptospirosis in a male ICR mouse model.
    Vaccine. 2026;76:128331.
    PubMed         Abstract available
    
    
43. DUFOUR L, Drouin J, Dray-Spira R, Le Vu S, et al
    Uptake of HPV vaccination and associated factors in France: a nationwide study from 2007 to 2023.
    Vaccine. 2026;76:128308.
    PubMed         Abstract available
    
    
44. STEFKOVICS A, Ligeti AS, Koltai J
    Willingness to vaccinate in a future pandemic. Evidence from a vignette experiment.
    Vaccine. 2026;76:128284.
    PubMed         Abstract available
    
    
45. BOYCE MR, Sell TK
    Support for vaccine-related priorities included in the Make Our Children Healthy Again Assessment and impacts on trust in vaccine safety: a national survey of parents in the United States.
    Vaccine. 2026;76:128336.
    PubMed         Abstract available
    
    
46. ALMEIDA GG, Pinto JA, Pinto PM, da Silva LB, et al
    Corrigendum to "Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19" [Vaccine 64 (2025) 127756].
    Vaccine. 2026;76:128316.
    PubMed        
    
    

    
    Virology

47. SHARMA S, Thivierge B, Liu Q
    A bivalent subunit vaccine elicits robust immune responses and neutralizing antibodies against genogroup 1b and 2b porcine epidemic diarrhea viruses.
    Virology. 2026;617:110824.
    PubMed         Abstract available
    
    
48. WUBSHET AK, Ding Y, Zhou L, Wang Y, et al
    Development of baculovirus-derived bovine parvovirus VP2based chimeric virus-like particles co-displaying SAT2 FMDV VP1 B- and T-cell epitopes and evaluation of humoral and cellular immune responses in BALB/c mice.
    Virology. 2026;617:110812.
    PubMed         Abstract available
    
    
49. LIU H, Ma Y, Hou F, Teng Z, et al
    Combination immunization with mRNAs encoding PRRSV antigens enhances immune responses and confers protective immunity against highly pathogenic PRRSV in piglets.
    Virology. 2026;617:110810.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum